drugset / Trial / NCT00847366
Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma
Non-randomizedCrossoverOpen-labelTreatment
Summary
This is an open label trial for patients currently enrolled in other perifosine trials.
Timeline
- Start
- 2008-05
- Primary completion
- 2012-12
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Perifosine | Small molecule | 50 mg | Oral |
| Subject | Perifosine | Small molecule | 150 mg | Oral |
| Subject | Perifosine | Small molecule | 300 mg | Oral |
| Subject | Perifosine | Small molecule | 900 mg | Oral |
| Subject | Tamoxifen | Small molecule | — | — |
| Background | Trastuzumab | Monoclonal antibody | 2 mg/kg | Intravenous |
| Background | Trastuzumab | Monoclonal antibody | 6 mg/kg | Intravenous |